Table 1. PD-L1 expression by immunohistochemistry in different studies.
Reference | Tumor type | Drug | IHC Ab | Cell location | Cut-off (%) | n (PD-L1) | PD-L1+ pt (%) | ORR (%) PD-L1+ | ORR (%) PD-L1- |
---|---|---|---|---|---|---|---|---|---|
Topalian et al.30 | Solid | Nivolumab | 5H1 | Tumor cells (mb) | 5 | 42 | 59.5 | 36 | 0 |
D'Incecco et al.59 | Lung | Gefitinib/Erlotinib | 58810 | Tumor cells | 5 | 98 | 53.1 | 61.2 | 34.8 |
Powles et al.60 | Bladder | MPDL3280A | SP142 | Tumor cells | 5 | 205 | 10.73 | 28.6 | 25.9 |
IC | 26.8 | 43.3 | 11.1 | ||||||
Herbst et al.61 | Lung | MPDL3280A | SP142 | Tumor cells (mb and cyto) | 5 | 53 | 24 | 33 | 22 |
IC | 26 | 46.1 | 18.2 | ||||||
Grosso et al.62 | Melanoma | Nivolumab | 28-8 | Tumor cells (mb) | 5 | 38 | 45 | 44 | 17 |
Brahmer et al.58 | Solid | Nivolumab | 5H1 | Tumor cells (mb) | 5 | 9 | 44.4 | 75 | 0 |
Garon et al.63 | Lung | Pembrolizumab | 22C3 | Tumor cells (mb) | 50 | 824 | 23.2 | 42.3 | 14.8 |
Konishi et al.64 | Lung | – | MIH1 | Tumor cells (mb and cyto) | 1 | 52 | 27.2 | – | – |
Dong et al.44 | Lung | – | 5H1 | Tumor cells (mb and cyto) | 10 | 21 | 95 | – | – |
Hamanishi et al.50 | Ovarian | – | 27A2 | Tumor cells | Moderate intensity | 70 | 68.6 | 80.2 | 52.6 |
Taube et al.65 | Solid | Nivolumab | 5H1 | Tumor cells (mb) | 5 | 41 | 56 | 39 | 6 |
IC | 56 | 35 | 11 |
Ab, antibody; cyto, cytoplasm; IC, immune cells; mb, membrane; ORR, objective response rate; pt, patient.